Details of the Drug Combinations

General Information of This Drug (ID: DMSYRBX)

• Drug Name: Atazanavir (DMSYRBX)
• Synonyms: 198904-31-3; Latazanavir; Zrivada; Reyataz; BMS-232632; BMS 232632; Atazanavir [INN:BAN]; CGP 73547; Atazanavir Base; UNII-QZU4H47A3S; CGP-73547; HSDB 7339; Reyataz (TN); ATV; QZU4H47A3S; CHEMBL1163; CHEBI:37924; (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5,6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; NCGC00182552-01; AK174307; DSSTox_CID_28617; DSSTox_RID_82887; DSSTox_GSID_48691; DR7; atazanavirum; ATZ; Atazanavirum; Atazanavir (INN); Reyataz, BMS-232632, Atazanavir; Reyataz(TM) (*1:1 sulfate*); Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate; METHYL [(1S,4S,5S,10S)-4-BENZYL-1,10-DI-TERT-BUTYL-5-HYDROXY-2,9,12-TRIOXO-7-(4-PYRIDIN-2-YLBENZYL)-13-OXA-3,7,8,11-TETRAAZATETRADEC-1-YL]CARBAMATE; Methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; (2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide

Indication

Human immunodeficiency virus infection; ICD 11: 1C62; Status: Approved [1]

• Therapeutic Class: Anti-HIV Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

18 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Atazanavir + Maraviroc	DC4NSKF	Maraviroc	HIV Infections	[2]
Atazanavir + Ritonavir	DCKM8IJ	Ritonavir	HIV Infections	[2]
Atazanavir + Ritonavir	DCBXVIY	Ritonavir	HIV	[3]
Atazanavir + Raltegravir	DCK60JV	Raltegravir	HIV	[4]
Atazanavir + Ritonavir	DCUIOGY	Ritonavir	Human Immunodeficiency Virus Type 1 (HIV-1)	[5]
Belinostat + Atazanavir	DCAM7II	Belinostat	Solid Tumor	[6]
Cobicistat + Atazanavir	DC3OP08	Cobicistat	Human Immunodeficiency Virus Type 1 (HIV-1)	[7]
Daclatasvir + Atazanavir	DC0QK6O	Daclatasvir	Hepatitis C	[8]
Lamivudine + Atazanavir	DCLTXS0	Lamivudine	Human Immunodeficiency Virus	[9]
Rifampicin + Atazanavir	DC2BHD2	Rifampicin	HIV Infections	[10]
Voriconazole + Atazanavir	DCZAJNU	Voriconazole	Human Immunodeficiency Virus Type 1 (HIV-1)	[5]
BMS-955176 + Atazanavir	DCT2R6D	BMS-955176	Infection, Human Immunodeficiency Virus	[11]
BMS-955176 + Atazanavir	DC2B72P	BMS-955176	Infection, Human Immunodeficiency Virus	[11]
Tenofovir + Atazanavir	DC0AQOM	Tenofovir	Infection, Human Immunodeficiency Virus	[12]
Lamivudine + Atazanavir	DCHS312	Lamivudine	HIV	[13]
Atazanavir + Ritonavir	DCRZS8N	Ritonavir	HIV, Combination Therapy	[14]
Emtricitabine + Atazanavir	DCG0IYQ	Emtricitabine	HIV	[15]
Nevirapine + Atazanavir	DCSVZKV	Nevirapine	HIV Infections	[16]

References

• [1] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [2] ClinicalTrials.gov (NCT00977756) IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
• [3] ClinicalTrials.gov (NCT01335698) Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients
• [4] ClinicalTrials.gov (NCT00768989) Phase IIB Pilot of Atazanavir + Raltegravir
• [5] ClinicalTrials.gov (NCT00833482) Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
• [6] ClinicalTrials.gov (NCT04184869) Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
• [7] ClinicalTrials.gov (NCT01837719) Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
• [8] ClinicalTrials.gov (NCT02565888) A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
• [9] ClinicalTrials.gov (NCT02652793) Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia
• [10] ClinicalTrials.gov (NCT00096850) Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults
• [11] ClinicalTrials.gov (NCT01803074) Study to Evaluate a HIV Drug for the Treatment of HIV Infection
• [12] ClinicalTrials.gov (NCT01384734) HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
• [13] ClinicalTrials.gov (NCT01620944) Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Nave Subjects, Followed by Treatment With ATV/RTV+3TC
• [14] ClinicalTrials.gov (NCT01332227) Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients
• [15] ClinicalTrials.gov (NCT00757783) Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment
• [16] ClinicalTrials.gov (NCT00355719) Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients